Fly News Breaks for December 18, 2019
Dec 18, 2019 | 09:02 EDT
B. Riley FBR analyst Andrew D'Silva initiated coverage of CorMedix with a Buy rating and $15 price target. The company's lead candidate, Neutrolin, has the potential to be the first FDA-approved catheter lock solution, D'Silva tells investors in a research note. With a New Drug Application expected in the first half of 2020, the analyst is modeling a U.S. commercial launch starting in the second half of 2021. He sees CorMedix's revenue growing to $135.5M in 2023.
News For CRMD From the Last 2 Days
There are no results for your query CRMD